Cargando…
Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
Immune-related adverse events (irAEs) pose a significant challenge for the widespread adoption of immuno-oncology therapies, but their symptoms can vary widely. In particular, the relationship between irAEs and pleural effusion (PE) in patients with advanced non-small cell lung cancer (NSCLC) remain...
Autores principales: | Xie, Xiao-Hong, Shen, Pan-Xiao, Wu, Jian-Hui, Qiu, Gui-Huan, Lin, Xin-Qing, Xie, Zhan-Hong, Qin, Yin-Yin, Zheng, Bin, Liu, Ming, Zhou, Cheng-Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399467/ https://www.ncbi.nlm.nih.gov/pubmed/37529904 http://dx.doi.org/10.1080/21645515.2023.2240689 |
Ejemplares similares
-
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021) -
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020) -
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
por: Liu, Yang, et al.
Publicado: (2021) -
Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023) -
Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy
por: Desai, Aakash P, et al.
Publicado: (2023)